Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Impact of VTD or VRD induction on stem-cell collection a Impact of VTD... | Download Scientific Diagram
Multiple Myeloma Hub on X: "#ASCO21 | Patients treated with dara+VTd/dara achieved higher responses and MRD negativity rates. 📢Share your experience with dara+VTd! How might the CASSIOPEIA results impact other trials exploring
When and How to Treat Relapsed Multiple Myeloma
Beyond the Congress Induction Therapy
Multiples Myelom: D-VTd in der Induktion und Konsolidierung
Die Erstlinientherapie des Multiplen Myeloms – aktueller Stand und neue Entwicklungen
EHA Library - The official digital education library of European Hematology Association (EHA)
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Frontiers | Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Maintenance therapies in Multiple Myeloma - ppt download
A20-15 - Daratumumab - Extract of dossier assessment - Version 1.0
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial | Haematologica
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression | VuMedi
Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 -
Daratumumab maintenance after treatment with VTd w/DARA and ASCT in pts with NDMM: CASSIOPEIA Part 2 - YouTube
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma - ScienceDirect
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial | Haematologica
Ben Derman on X: "CASSIOPEIA MRD analysis: Take a look at the top two PFS curves for Dara-VTd vs. VTd among MRD-negative patients. Doesn't seem like sustained MRD-negativity behaves the same? For
Vincent Rajkumar on X: "I am very impressed with the CASSIOPEIA Dara-VTD vs VTD trial. Especially HR post adjustment for maintenance & the trend for OS I will consider a quadruplet like
